New cephalosporins

Sheldon L. Kaplan

Research output: Contribution to journalArticlepeer-review


During the past 10 years, very few new cephalosporins have been introduced for pediatric use. Cefepime is a fourth-generation cephalosporin used for parenteral treatment of serious infections. Cefepime has enhanced activity against gram-negative enterics that often are resistant to multiple antibiotics, including those producing extended-spectrum β-lactamases or hyperproducing AmpC enzymes, and it retains good activity against gram-positive cocci. Cefepime is useful for treating nosocomial infections caused by multiresistant gram-negative enterics and has advantages over ceftazidime for empirical treatment of the febrile neutropenic child with cancer. Cefdinir is an extended-spectrum oral cephalosporin that has activity against organisms associated with upper respiratory tract infections comparable with that of cefuroxime or cefpodoxime. Cefdinir suspension is well tolerated by children and as a single daily dose is equivalent to amoxicillin-clavulanate for treating acute otitis media in children. Cefdinir is the oral cephalosporin to consider as second-line therapy for treatment of acute otitis media or acute bacterial sinusitis for children who are unresponsive to or intolerant of amoxicillin-clavulanate.

Original languageEnglish (US)
Pages (from-to)169-174
Number of pages6
JournalSeminars in Pediatric Infectious Diseases
Issue number3
StatePublished - 2001

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)


Dive into the research topics of 'New cephalosporins'. Together they form a unique fingerprint.

Cite this